Zobrazeno 1 - 10
of 95
pro vyhledávání: '"Shuji Joho"'
Autor:
Masaki Nakagaito, Teruhiko Imamura, Shuji Joho, Ryuichi Ushijima, Makiko Nakamura, Koichiro Kinugawa
Publikováno v:
BMC Cardiovascular Disorders, Vol 21, Iss 1, Pp 1-8 (2021)
Abstract Background Sodium-glucose cotransporter 2 inhibitor (SGLT2i) reduces the risk of the composite renal endpoint and weakens the progressive decline in renal function in patients with chronic heart failure (HF). However, a detailed mechanism of
Externí odkaz:
https://doaj.org/article/a632534d158f4a3380862f9775d0dc9c
Publikováno v:
Medicina, Vol 59, Iss 2, p 401 (2023)
Combined cases of hypertrophic obstructive cardiomyopathy (HOCM) and pulmonary arterial hypertension (PAH) are rare and have a management dilemma. Although preload is crucial in the management of HOCM, anti-PAH agents dramatically change the preload,
Externí odkaz:
https://doaj.org/article/9f1f1b321f884be6bc4bf9758c2cd78f
Autor:
Ryoko Shibuya, Kousuke Baba, Risako Furuta, Hiroki Maesaka, Hiroaki Hirosawa, Tadashi Bando, Akira Oshima, Hiroshi Onoda, Takamasa Nukui, Nobuhiro Dougu, Shuji Joho, Yuji Nakatsuji
Publikováno v:
Internal Medicine; 2024, Vol. 63 Issue 15, p2193-2198, 6p
Autor:
Masakazu Hori, Teruhiko Imamura, Shinya Kajiura, Shuhei Tanaka, Hiroshi Ueno, Kazuaki Fukahara, Koichiro Kinugawa, Shuji Joho
Publikováno v:
Internal Medicine. 61:1015-1019
A de novo cardiac malignant tumor is rare and sometimes challenging to diagnose. We encountered a 67-year-old man without any medical history complaining of dyspnea on effort. On admission, his hemodynamics were deteriorated due to cardiac tamponade,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21d31f192c4933de7d7f4ad1a494fed3
https://doi.org/10.2169/internalmedicine.8250-21
https://doi.org/10.2169/internalmedicine.8250-21
Autor:
Shuji Joho, Koichiro Kinugawa
Publikováno v:
Nihon Naika Gakkai Zasshi. 111:255-262
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::009b7f6c365ad38417eec4b8210d8a6a
https://doi.org/10.2169/naika.111.255
https://doi.org/10.2169/naika.111.255
Publikováno v:
Circulation Reports
Background: Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has demonstrated survival benefit and reduces heart failure hospitalization compared with enalapril in patients with heart failure and reduced ejection fraction. However,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73edb9e46f53b282170ce8d91fc9bdeb
https://doi.org/10.1253/circrep.cr-21-0068
https://doi.org/10.1253/circrep.cr-21-0068
Autor:
Teruhiko Imamura, Nobuyuki Fukuda, Masakazu Hori, Koichiro Kinugawa, Hiroshi Ueno, Shuhei Tanaka, Hiroshi Onoda, Naoya Kataoka, Mitsuo Sobajima, Makiko Nakamura, Shuji Joho, Ryuichi Ushijima
Publikováno v:
Circulation Reports
Background: The prognostic impact of urinary isoxanthopterin (U-IXP), a recently proposed marker of oxidative stress, in patients with heart failure remains unknown. Methods and Results: Patients who were admitted to our institute for decompensated h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7786783d4960f81789f2ab0d5659cb3
http://europepmc.org/articles/PMC8578125
http://europepmc.org/articles/PMC8578125
Autor:
Makiko Nakamura, Ryuichi Ushijima, Teruhiko Imamura, Shuji Joho, Masaki Nakagaito, Koichiro Kinugawa
Publikováno v:
International Heart Journal. 62:885-890
Sodium-glucose cotransporter 2 inhibitor (SGLT2i) reduces mortality and morbidity in patients with chronic heart failure (HF). However, the clinical implication of SGLT2i therapy in patients with acute decompensated HF remains uncertain. We prospecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9099b56fddd8bd2ae13291c753f5a08f
https://doi.org/10.1536/ihj.21-022
https://doi.org/10.1536/ihj.21-022
Autor:
Masaki Nakagaito, Ryuichi Ushijima, Teruhiko Imamura, Koichiro Kinugawa, Shuji Joho, Makiko Nakamura
Publikováno v:
International Heart Journal. 62:843-849
The DAPA-HF trial demonstrated that sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduced worsening heart failure (HF) events in chronic HF patients with or without type 2 diabetic mellitus (T2DM). However, it remains unclear whether the effecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26d85d97d85b3829d374e6599fc3b519
https://doi.org/10.1536/ihj.20-764
https://doi.org/10.1536/ihj.20-764
Autor:
Masaki Nakagaito, Teruhiko Imamura, Shuji Joho, Ryuichi Ushijima, Makiko Nakamura, Koichiro Kinugawa
Publikováno v:
Journal of Clinical Medicine; Volume 11; Issue 17; Pages: 5027
Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce the risk of hospitalization for heart failure (HF) or death from cardiovascular causes among patients with chronic HF. However, little is known about the specific factors associate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca71f0f296ec2fcb3ee475046bebeb4b